一分钟看懂
这是一项关于非小细胞肺癌的II 期研究，登记的药物或干预包括JNJ-90301900；Durvalumab；Concurrent Chemo/Radiation Therapy (cCRT)；Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin；Concurrent Chemo/Ra，当前状态为招募中。登记地点显示中国东莞、广州、济南有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
JNJ-90301900；Durvalumab；Concurrent Chemo/Radiation Therapy (cCRT)；Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin；Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel · II 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出5项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出5项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Dongguan People s Hospital · 东莞
- The First Affiliated Hospital Sun Yat sen University · 广州
- The Affiliated Cancer Hospital of Shandong First Medical University · 济南
公开的入选条件
- * Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator an
- * Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months prior to enrollment/randomization
- * Have locally advanced unresectable stage III NSCLC according to the eighth edition lung cancer stage classification
- * Have at least 1 target lesion (primary lung lesion or involved lymph node\[s\]) per RECIST version 1.1 that is amenable to intratumoral and/or intranodal injection and intensity modulated radiation therapy (IMRT) as determined by the investigator at screenin
- * Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06667908；登记信息更新于 2026-09-25。